Document is current

Article History

Received: 22 May 2023

Accepted: 25 August 2023

First Online: 26 September 2023

Declarations

:

: Martin Kolb reports research funding from Boehringer Ingelheim (BI), Pieris, Roche; consulting fees from AbbVie, Algernon, Bellerophon, BI, Cipla, CSL Behring, Horizon, LabCorp, Roche, ShouTi, United Therapeutics; fees for speaking from BI, Novartis, Roche; fees for expert testimony from Roche; has participated on a data safety monitoring board or advisory board for United Therapeutics and LabCorp; and receives an allowance as Chief Editor of the European Respiratory Journal. Kevin R Flaherty reports grants paid to his institution from BI; royalties or licenses from UpToDate; consulting fees from Arrowhead, AstraZeneca, Bellerophon, BI, CSL Behring, Daewoong, DevPro, Dispersol, FibroGen, Horizon Therapeutics, Immunet, Insilico, Lupin, NeRRe Therapeutics, Pliant, Polarean, Pure Health, PureTech, Respivant, Roche/Genentech, Shionogi, Sun Pharmaceuticals, Trevi, United Therapeutics, Vicore. Rafael S Silva has nothing to report. Antje Prasse reports consulting fees from BI, CSL Behring, Novartis; fees for speaking from BI, Euroimmun, Gilead, Novartis; support for travel from BI; she holds a leadership or fiduciary role as a coordinator of the ILD group of the European Reference Network-lung. Carlo Vancheri reports grants paid to his institution from Roche; consulting fees from BI and Roche; fees for speaking from AstraZeneca, BI, GlaxoSmithKline, Glycocore, Menarini, Roche; payments for expert testimony and support for travel from BI and Roche; has participated on a data safety monitoring board or advisory board for BI, LabCorp, Roche; and his institution has received equipment, materials, drugs, or other services from BI, Biogen, Bristol Myers Squibb, FibroGen, Galapagos, Gilead, GlaxoSmithKline, Novartis, Pliant, Respivant Sciences, Roche, Sanofi. Heiko Mueller and Kamila Sroka-Saidi are employees of BI. Athol U Wells reports consulting fees from BI, Roche, Veracyte and fees for speaking from BI and Roche. Martin Kolb, Kevin R Flaherty and Athol U Wells were members of the INBUILD trial steering committee.

: The INBUILD trial protocol was approved by an Ethics Committee or Institutional Review Board at all the participating centres. The INBUILD trial was carried out in compliance with the protocol and with the principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for Good Clinical Practice of the International Conference on Harmonisation. The trial was approved by the local authorities. All patients provided written informed consent prior to their participation.